Global Routine Vaccination Coverage, 2018

Megan Peck, PhD1,2; Marta Gacic-Dobo, MSc3; Mamadou S. Diallo4, PhD; Yoann Nedelec5; Samir S. Sodha, MD3; Aaron S. Wallace, PhD2

Endorsed by the World Health Assembly in 2012, the Global Vaccine Action Plan 2011–2020 (GVAP) (1) calls on all countries to reach ≥90% national coverage with all vaccines in the country’s national immunization schedule by 2020. Building on previous analyses (2) and using the World Health Organization (WHO) and United Nations Children’s Fund (UNICEF) global vaccination coverage estimates as of 2018, this report presents global, regional, and national vaccination coverage estimates and trends, including vaccination dropout rates. According to these estimates, global coverage with the first dose of diphtheria and tetanus toxoids and pertussis-containing vaccine (DTP1) remained relatively unchanged from 2010 (89%) to 2018 (90%). Global coverage with the third DTP dose (DTP3) followed a similar global trend to that of DTP1, remaining relatively consistent from 2010 (84%) to 2018 (86%) (3). Globally, 19.4 million children (14%) were not fully vaccinated in 2018, and among them, 13.5 million (70%) did not receive any DTP doses. Overall, dropout rates from DTP1 to DTP3 decreased globally from 6% in 2010 to 4% in 2018. Global coverage with the first dose of measles-containing vaccine (MCV1) remained between 84% and 86% during 2010–2018. Among countries that offer a second MCV dose (MCV2) during the second year of life, coverage increased from 19% in 2007 to 54% in 2018; among countries offering MCV2 to older age groups (children aged 3–14 years), coverage also increased, from 36% in 2007 to 69% in 2018 (3). Globally, the estimated difference in coverage with MCV1 and MCV2 in 2018 was 17%. However, among new and underused vaccines, global coverage increased from 2007 to 2018 for completed series of rotavirus vaccine, pneumococcal conjugate vaccine (PCV), rubella vaccine, Haemophilus influenzae type b vaccine (Hib), and hepatitis B vaccine (HepB). To reach global vaccination coverage goals for vaccines recommended during childhood, adolescence, and adulthood, tailored strategies that address local determinants for incomplete vaccination are needed, including targeting hard-to-reach and hard-to-vaccinate populations.

Since the establishment of WHO’s Expanded Programme on Immunization in 1974 to ensure access to Bacille Calmette-Guérin vaccine (BCG), DTP, polio vaccine (Pol), and MCV, an increasing number of vaccines and doses have been introduced (4). However, some of these vaccines are recommended after the first birthday; this has added complexity to immunization programs, which typically targeted children during the first year of life. To estimate national vaccination coverage, WHO and UNICEF annually review all available country data, including administrative and survey-based coverage* (5,6). In general, only doses administered through routine immunization visits

*For a given vaccine, the administrative coverage is the number of vaccine doses administered to persons in a specified target group divided by the estimated target population. Doses administered during routine immunization visits are counted, but doses administered during supplemental immunization activities (mass campaigns) usually are not. During vaccination coverage surveys, a representative sample of households is visited, and caregivers of children in a specified target age group (e.g., aged 12–23 months) are interviewed. Dates of vaccination are transcribed from the child’s home-based record, recorded according to caregiver recall, or transcribed from health facility records. Survey-based vaccination coverage is calculated as the proportion of persons in a target age group who received a vaccine dose.
Morbidity and Mortality Weekly Report

Among the 19.4 million children who failed to receive DTP3 in 2018, 11.7 million (60%) lived in 10 countries, including 5.6 million (29%) who lived in India and Nigeria. Within

Low-income economies are defined as those with a gross national income (GNI) per capita in USD in 2018 of ≤$1,025; middle-income economies are those with a GNI per capita of $1,026–12,375; and high-income economies are those with a GNI per capita of ≥$12,376, calculated using the World Bank Atlas method. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups.

Gavi eligibility includes low- and middle-income countries eligible to receive financial assistance through grants contingent on a country’s GNI per capita. Eligibility is defined as a country’s average 3-year GNI per capita in USD of ≤$1,580. As GNI increases, a country moves through Gavi’s different eligibility phases until reaching the transition phase when GNI exceeds the eligibility threshold. https://www.gavi.org.

The MMWR series of publications is published by the Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30329-4027.

Suggested citation: [Author names; first three, then et al., if more than six.] [Report title]. MMWR Morb Mortal Wkly Rep 2019;68:[inclusive page numbers].

MMWR Editorial and Production Staff (Weekly)

Charlotte K. Kent, PhD, MPH, Editor in Chief
Jacqueline Gindler, MD, Editor
Mary Dott, MD, MPH, Online Editor
Terisa F. Rutledge, Managing Editor
Douglas W. Weatherwax, Lead Technical Writer-Editor
Glenn Damon, Soumya Dunworth, PhD; Teresa M. Hood, MS, Technical Writer-Editors

Martha E. Boyd, Lead Visual Information Specialist
Maureen A. Leahy, Julia C. Martinro, Stephen R. Spriggs, Tong Yang, Visual Information Specialists
Quang M. Doan, MBA, Phyllis H. King, Terraye M. Starr, Moua Yang, Information Technology Specialists

MMWR Editorial Board

Timothy F. Jones, MD, Chairman
Robin Ikeda, MD, MPH
Phyllis Meadows, PhD, MSN, RN
Jewel Mullen, MD, MPH, MPA
Jeff Niederdeppe, PhD
Patricia Quinlisk, MD, MPH

Stephen C. Redd, MD
Patrick L. Remington, MD, MPH
Carlos Roig, MS, MA
William Schaffner, MD
Morgan Bobb Swanson, BS
TABLE 1. Coverage with vaccines administered through routine immunization programs,* by vaccine and World Health Organization region — worldwide, 2018

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>No. (%) of countries with vaccine in schedule</th>
<th>Total (worldwide)</th>
<th>African</th>
<th>Americas</th>
<th>Eastern Mediterranean</th>
<th>European</th>
<th>South-East Asia</th>
<th>Western Pacific</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BCG</td>
<td>156 (80)</td>
<td>89</td>
<td>80</td>
<td>91</td>
<td>87</td>
<td>93</td>
<td>91</td>
<td>96</td>
</tr>
<tr>
<td>DTP1</td>
<td>194 (100)</td>
<td>90</td>
<td>84</td>
<td>92</td>
<td>87</td>
<td>97</td>
<td>92</td>
<td>94</td>
</tr>
<tr>
<td>DTP3</td>
<td>194 (100)</td>
<td>86</td>
<td>76</td>
<td>87</td>
<td>82</td>
<td>94</td>
<td>89</td>
<td>93</td>
</tr>
<tr>
<td>HepB birth dose</td>
<td>108 (56)</td>
<td>42</td>
<td>4</td>
<td>68</td>
<td>33</td>
<td>39</td>
<td>48</td>
<td>83</td>
</tr>
<tr>
<td>HepB third dose</td>
<td>189 (97)</td>
<td>84</td>
<td>76</td>
<td>81</td>
<td>82</td>
<td>84</td>
<td>89</td>
<td>90</td>
</tr>
<tr>
<td>Hib3</td>
<td>191 (98)</td>
<td>72</td>
<td>76</td>
<td>87</td>
<td>82</td>
<td>76</td>
<td>87</td>
<td>23</td>
</tr>
<tr>
<td>MCV1</td>
<td>194 (100)</td>
<td>86</td>
<td>74</td>
<td>90</td>
<td>82</td>
<td>95</td>
<td>89</td>
<td>95</td>
</tr>
<tr>
<td>MCV2</td>
<td>173 (89)</td>
<td>69</td>
<td>26</td>
<td>82</td>
<td>74</td>
<td>91</td>
<td>80</td>
<td>91</td>
</tr>
<tr>
<td>PCV3</td>
<td>144 (74)</td>
<td>47</td>
<td>73</td>
<td>82</td>
<td>53</td>
<td>78</td>
<td>17</td>
<td>13</td>
</tr>
<tr>
<td>Pol3</td>
<td>194 (100)</td>
<td>85</td>
<td>74</td>
<td>87</td>
<td>82</td>
<td>93</td>
<td>89</td>
<td>95</td>
</tr>
<tr>
<td>RCV1</td>
<td>170 (88)</td>
<td>69</td>
<td>32</td>
<td>90</td>
<td>45</td>
<td>95</td>
<td>83</td>
<td>94</td>
</tr>
<tr>
<td>Rota_last</td>
<td>101 (52)</td>
<td>35</td>
<td>48</td>
<td>73</td>
<td>47</td>
<td>25</td>
<td>24</td>
<td>1</td>
</tr>
</tbody>
</table>

Abbreviations: BCG = Bacille Calmette-Guérin vaccine; DTP3 = third dose of diphtheria and tetanus toxoids and pertussis-containing vaccine; HepB = hepatitis B vaccine; Hib3 = third dose of Haemophilus influenzae type b vaccine; MCV1 = first dose of measles-containing vaccine; MCV2 = second dose of measles-containing vaccine; PCV3 = third dose of pneumococcal conjugate vaccine; Pol3 = third dose of polio vaccine; RCV1 = first dose of rubella-containing vaccine; Rota_last = final dose of rotavirus vaccine series (number of doses to complete the series varies among vaccine products).

* Coverage is based on 156 countries with BCG in the national schedule, whereas coverage for all other vaccines is based on 194 countries worldwide or all countries in the specified region. Administrative coverage is the number of vaccine doses administered to persons in a specified target group divided by the estimated target population. Doses administered during routine immunization visits are counted, but doses administered during supplemental immunization activities (mass campaigns) usually are not. During vaccination coverage surveys, a representative sample of households is visited and caregivers of children in a specified target age group (e.g., aged 12–23 months) are interviewed. Dates of vaccination are transcribed from the child’s home-based record, recorded according to caregiver recall, or transcribed from health facility records. Survey-based vaccination coverage is calculated as the proportion of persons in a target age group who received a vaccine dose.

TABLE 2. Differences in vaccination coverage for selected vaccine doses given during the first year of life or recommended at the same age, by World Health Organization (WHO) region, Gavi eligibility, and economic classification — worldwide, 2018

<table>
<thead>
<tr>
<th>Country grouping</th>
<th>Total no. of countries</th>
<th>DTP1 to DTP3 dropout, %*,†</th>
<th>DTP3 to PCV3 difference, %§,¶</th>
<th>MCV1 to MCV2 difference, %§,¶</th>
<th>BCG to HepB birth dose difference, %§,¶</th>
<th>DTP3 to Pol3 last difference, %§,¶</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total worldwide</td>
<td>194</td>
<td>4</td>
<td>39</td>
<td>17</td>
<td>47</td>
<td>51</td>
</tr>
<tr>
<td>WHO region</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>African</td>
<td>47</td>
<td>10</td>
<td>3</td>
<td>48</td>
<td>76</td>
<td>28</td>
</tr>
<tr>
<td>Americas</td>
<td>35</td>
<td>5</td>
<td>5</td>
<td>8</td>
<td>23</td>
<td>14</td>
</tr>
<tr>
<td>Eastern Mediterranean</td>
<td>21</td>
<td>6</td>
<td>29</td>
<td>8</td>
<td>54</td>
<td>35</td>
</tr>
<tr>
<td>European</td>
<td>53</td>
<td>3</td>
<td>16</td>
<td>4</td>
<td>54</td>
<td>69</td>
</tr>
<tr>
<td>South-East Asia</td>
<td>11</td>
<td>3</td>
<td>72</td>
<td>9</td>
<td>43</td>
<td>65</td>
</tr>
<tr>
<td>Western Pacific</td>
<td>27</td>
<td>1</td>
<td>80</td>
<td>4</td>
<td>13</td>
<td>92</td>
</tr>
<tr>
<td>Gavi-eligible countries</td>
<td>Worldwide</td>
<td>68</td>
<td>7</td>
<td>33</td>
<td>26</td>
<td>61</td>
</tr>
<tr>
<td>Economic classification**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low-income country</td>
<td>30</td>
<td>7</td>
<td>10</td>
<td>46</td>
<td>81</td>
<td>25</td>
</tr>
<tr>
<td>Middle-income country</td>
<td>107</td>
<td>4</td>
<td>49</td>
<td>12</td>
<td>38</td>
<td>57</td>
</tr>
<tr>
<td>High-income country</td>
<td>57</td>
<td>3</td>
<td>5</td>
<td>2</td>
<td>55</td>
<td>46</td>
</tr>
</tbody>
</table>

Abbreviations: BCG = Bacille Calmette-Guérin vaccine; DTP3 = third dose of diphtheria and tetanus toxoids and pertussis-containing vaccine; HepB = hepatitis B vaccine; MCV1 = first dose of measles-containing vaccine; MCV2 = second dose of measles-containing vaccine; PCV3 = third dose of pneumococcal conjugate vaccine; Pol3 = third dose of polio vaccine; Rota_last = final dose of rotavirus vaccine series (number of doses to complete the series varies among vaccine products).

* Dropout = those who received 1 or 2 DTP doses but did not receive DTP3; calculated using the formula: [(DTP1-DTP3)/DTP1] x 100.
† Only includes countries that have introduced both vaccines and have a WHO/United Nations Children’s Fund (UNICEF) estimate of coverage for both vaccines.
§ Difference = percentage point difference between coverage with the first vaccine and the second vaccine (e.g., BCG coverage versus HepB birth dose coverage).
¶ Includes countries that have not yet introduced both vaccines or countries that do not have a WHO/UNICEF estimate of coverage for both vaccines.
** Low-income economies are defined as those with a gross national income (GNI) per capita in USD of ≤$1,025; middle-income economies are those with a GNI per capita of $1,026–12,375; and high-income economies are those with a GNI per capita of ≥$12,376, calculated using the World Bank Atlas method. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups.

these 10 countries, among all children who did not receive DTP3, the percentage who failed to receive any DTP doses ranged from 54% to 97%, and the percentage who dropped out between DTP1 and DTP3 ranged from 3% to 46% (Figure). In 2018, MCV1 coverage ranged from 74% in the African Region to 95% in the Western Pacific and European regions (Table 1). Globally, 118 (61%) countries achieved the GVAP 2020 target of ≥90% national MCV1 coverage (> in 2018,
FIGURE. Estimated number of children who were left out* or dropped out† of the immunization program during the first year of life among the 10 countries with the most incompletely vaccinated children and cumulative percentage of all incompletely vaccinated children worldwide accounted for by these 10 countries, 2018

Abbreviations: DRC = Democratic Republic of the Congo; DTP1 = 1 dose of diphtheria and tetanus toxoids and pertussis-containing vaccine; DTP3 = third dose of diphtheria and tetanus toxoids and pertussis-containing vaccine.

* Never received DTP1.
† Received DTP1 but did not receive DTP3.

Among all countries, including those that have not yet introduced MCV2, coverage with the second dose by WHO region ranged from 26% in the African Region to 91% in the Western Pacific and European regions (Table 2). Differences in MCV1 and MCV2 coverage varied by region, economic classification, and year of MCV2 introduction. Among regions, the largest difference in coverage between MCV1 and MCV2 was in the African Region (48%), and the smallest (4%) was in the European and Western Pacific regions. By economic classification, the difference in coverage between MCV1 and MCV2 was 46% among low-income countries, 12% in middle-income countries, and 2% in high-income countries. Among the 165 countries that had introduced MCV2 and reported an MCV2 estimate, the largest difference between MCV1 and MCV2 coverage (17%) was estimated among 34 countries that introduced MCV2 during 2010–2017, compared with 5% among 131 countries that introduced the second dose before 2010.

Rotavirus vaccine had been introduced in 101 (52%) countries by 2018. Global coverage with the completed rotavirus series approximately quadrupled, from 8% in 2010 to 35% in 2018. During this period, global coverage also increased for the completed series of PCV (from 11% to 47%), rubella vaccine (35% to 69%), Hib (40% to 72%), and HepB (birth dose: 28% to 42%; 3-dose series: 73% to 84%) (Table 1).

Among all countries (including those that have not introduced the vaccine), the difference in coverage with BCG and HepB birth dose was 47% globally, with the largest difference (76%) in the African Region and the smallest (13%) in the Western Pacific Region (Table 2). The difference between DTP3 and PCV3 coverage was estimated at 39% globally and varied by region, from 3% in the African Region to 80% in the Western Pacific Region. The difference between DTP3 and the final dose of rotavirus vaccine coverage was 51% globally, ranging from 92% in the Western Pacific Region to 14% in the Americas.

Discussion

Substantial progress has been made in vaccination coverage throughout the world since establishment of the Expanded Programme on Immunization in 1974; in 2018, among countries with available data, 90% of children received at least 1 dose of DTP, and 86% received 3 DTP doses and at least 1 dose of MCV. However, important challenges to achieving high immunization coverage levels for all recommended vaccines remain. Fewer than two thirds of all countries globally reached the GVAP 2020 target of ≥90% national coverage with DTP3 (66%) and MCV1 (61%). Regional differences in vaccination coverage and dropout rates exist, particularly for vaccines offered beyond the first year of life, and need to be
Summary
What is already known about this topic?
Since 1974, global coverage with vaccines to prevent tuberculosis, diphtheria, tetanus, pertussis, poliomyelitis, and measles has increased from <5% to 86%.

What is added by this report?
Global coverage with the third dose of diphtheria and tetanus toxoids and pertussis-containing vaccine has not increased above 86% since 2010. Coverage varies across regions and countries, with lower coverage in lower-income countries.

What are the implications for public health practice?
Equitable access to immunization to achieve and sustain high coverage can be enhanced through financial and technical support for program strengthening and vaccine introductions in lower-income settings, community engagement to increase vaccination acceptance and demand, collection and use of vaccination data, and commitment to improving immunization services.

addressed through context-specific strategies to reach global, regional, and national immunization coverage goals.

Establishing vaccination contact points during the second year of life and among targeted age groups, including adolescents and pregnant women, is a core component of the GVAP life-course approach. Countries that recently introduced MCV2 into vaccination visits beyond the first year of life still face large gaps in coverage between MCV1 and MCV2. These gaps highlight the challenge of establishing new contact visits and the need for systemic, evidence-informed strategies to address communication and service delivery and improve data systems around vaccine introduction. Recent research highlights the need for a well-organized social mobilization plan targeted to both health care providers and caregivers to ensure that stakeholders understand the importance of these new contact points (8). One component of reducing gaps in coverage between vaccines recommended at the same age is elimination of missed opportunities for vaccination; programs should ensure that existing vaccination sites have a secure continuous supply of vaccines and that providers use every health care opportunity to assess vaccination status and administer needed vaccines (9). Most African countries (79%) received Gavi funds to support introductions of PCV and rotavirus vaccines; the small differences in the 2018 coverage with these vaccines and DTP3 in the region highlight the importance of this support.

The findings in this report are subject to at least three limitations. First, limitations in data quality (e.g., inaccuracies in vaccination coverage reporting at lower administrative levels and target population information) can result in inaccurate estimations of administrative vaccination coverage. Second, parental recall errors could affect survey-based estimates of coverage (5,10). Finally, conflict-affected countries are likely to have limited external evaluation of coverage levels, which could limit the accuracy of coverage estimates.

Tailoring strategies to target hard-to-reach and hard-to-vaccinate populations and strengthening immunization systems for administering vaccines recommended beyond infancy are essential to ensure increases in vaccination coverage and disease reduction. Improvements in infrastructure and capacity should be made to improve data quality, particularly enhancement of timeliness and completeness of reporting. Improving initiation and completion of vaccination series that have already been integrated into vaccine schedules, particularly in the African, Americas, Eastern Mediterranean, and Western Pacific regions, is critical to achieving global immunization goals and disease reduction targets (8).

Corresponding author: Megan Peck, okv4@cdc.gov. 404-718-7187.

References
